Clinical Trial

A Study of FZ-AD005 in Patients With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 4, 2026 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
A First-in-Human, Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of FZ-AD005 in Patients with Advanced Solid Tumors.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-05-16; most recent amendment 2026-03-02.
Status change: Not Yet Recruiting → Recruiting 2024-07-23
Trial Details
NCT Number NCT06424665
Lead Sponsor Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Conditions Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma)
Enrollment 162 participants
Start Date 2024-07-03
Primary Completion 2026-08-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-04